BDX logo

BDX

Becton, Dickinson and CompanyNYSEHealthcare
$154.51-1.17%OpenMarket Cap: $55.98B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

31.86

PEG

18.34

P/B

1.74

P/S

2.55

EV/EBITDA

14.62

DCF Value

$1,365.05

FCF Yield

4.7%

Div Yield

2.3%

Margins & Returns

Gross Margin

45.8%

Operating Margin

12.4%

Net Margin

8.0%

ROE

6.9%

ROA

9.2%

ROIC

4.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 2026$5.25B$382.0M$1.34
Q4 2025$5.89B$493.0M$1.72
FY 2025$21.84B$1.68B$5.83
Q3 2025$5.51B$574.0M$2.00

Analyst Ratings

View All
Argus ResearchBuy
2026-03-23
CitigroupBuy
2026-02-11
Wells FargoEqual Weight
2026-02-10
RBC CapitalSector Perform
2026-02-10
Piper SandlerNeutral
2026-02-10

Trading Activity

Insider Trades

View All
Feld Michaelofficer: EVP, Chief Revenue Officer
SellFri Mar 27
Minnix Laneshaofficer: EVP and General Counsel
SellTue Mar 17
Minnix Laneshaofficer: EVP and General Counsel
SellTue Mar 17
Spikner Pamela L.officer: SVP Controller & CAO
SellWed Mar 04
Roque Vitorofficer: Interim CFO
SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

0.35

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Peers